Turret Capital and SOSV, global investment firms for life sciences and biotech companies, launched Sable on Jan. 15. The biotech beauty company, a discovery from Columbia University Medical Center, is actively creating topicals for body contouring support following aesthetic treatments and lifestyle changes, like GLP-1 therapies. Sable's first product line is currently in development.
Preclinical research studies for this product line demonstrated that an undisclosed ingredient could be selectively taken up by fat cells and achieve up to 70% reduction in fat cell volume, per a Jan. 15 press release. Sable will further develop this exclusively licensed asset into an advanced topical formulation of body creams.
The company release states that this topical is specifically for individuals seeking to enhance the visual definition of specific areas with stubborn concerns, or looking to support wellness transitions or sustain body enhancements following professional aesthetic treatments.
"By translating complex research into thoughtfully designed consumer products, we're redefining the limits of topical body care,” said Daniel Chai, MD,the Founder and CEO of Sable. “Sable is focused on helping people achieve and maintain their desired aesthetic look through evidence-based innovation that supports long-term body confidence.”
